Background Every winter, respiratory syncytial virus (RSV) disease results in thousands of
cases in Norwegian children under 5 years of age. We aim to assess the RSV-related …

Background Respiratory syncytial virus (RSV) imposes a substantial burden on pediatric
hospital capacity in Europe. Promising prophylactic interventions against RSV including …

INTRODUCTION: Respiratory syncytial virus (RSV) infection is one of the major causes of
respiratory illness in infants, infecting virtually every child before the age of 2 years …

Background Respiratory syncytial virus (RSV) is a leading cause of respiratory disease in
young children. A number of mathematical models have been used to assess the cost …

Background Vaccines and prophylactic antibodies against respiratory syncytial virus (RSV)
are in development and likely to be available in the next 5–10 years. The most efficient way …

Background Two new products for preventing Respiratory Syncytial Virus (RSV) in young
children have been licensed: a single-dose long-acting monoclonal antibody (la-mAB) and a …

Objectives Interventions to prevent childhood respiratory syncytial virus (RSV) disease are
limited and costly. New interventions are in advanced stages of development and could be …

Objectives Model-based cost-effectiveness analyses on maternal vaccine (MV) and
monoclonal antibody (mAb) interventions against respiratory syncytial virus (RSV) use …

Aim The cost-effectiveness of passive immunisation against respiratory syncytial virus (RSV)
in the Netherlands was studied by assessing incremental costs to prevent one …

Background New prevention strategies for respiratory syncytial virus (RSV) are emerging,
but it is unclear if they will be cost-effective in low-and middle-income countries. We …